title: Should nicorandil infusion be adapted in dialysis-dependent patients undergoing continuous renal replacement therapy after cardiac surgery?
abstract: In this report, we studied whether plasma concentration of nicorandil is maintained effectively and safely in dialysis-dependent patients with stage 5 chronic kidney disease (CKD5D) undergoing continuous renal replacement therapy (CRRT). Participants consisted of 10 patients undergoing CRRT after cardiac surgery. CRRT was performed with an effluent flow rate of either 600 mL/h (low-flow group; n = 5) or 1800 mL/h (high-flow group; n = 5). Nicorandil was infused intravenously at 0.1 mg/kg/h for more than 15 h starting 8 h before and 7 h after the start of CRRT. Plasma nicorandil concentrations were measured from arterial blood lines 1 h before and 7 h after CRRT initiation. Nicorandil clearance by CRRT was also calculated 1 h after CRRT initiation. Nicorandil plasma concentrations before and 7 h after CRRT initiation were 68.0 ng/mL and 74.6 ng/mL, respectively. Nicorandil clearance 1 h after CRRT initiation was 20.2 mL/min. Increasing the effluent flow rate from 600 mL/h to 1800 mL/h tended to increase nicorandil clearance. When nicorandil was infused intravenously during CRRT at 0.1 mg/kg/h in patients with CKD5D, plasma nicorandil concentrations were maintained within an effective concentration range.
authors.affiliation: Department of Anesthesiology and Intensive Care, Faculty of Medicine, Oita University, Yufu City, Oita, Japan. yasu@oita-u.ac.jp
authors.forename: Norihisa
authors.initials: N
authors.lastname: Yasuda
authors.forename: Koji
authors.initials: K
authors.lastname: Goto
authors.forename: Ryo
authors.initials: R
authors.lastname: Shitomi
authors.forename: Yoshifumi
authors.initials: Y
authors.lastname: Ohchi
authors.forename: Takakuni
authors.initials: T
authors.lastname: Abe
authors.forename: Shunsuke
authors.initials: S
authors.lastname: Yamamoto
authors.forename: Seigo
authors.initials: S
authors.lastname: Hidaka
authors.forename: Takayuki
authors.initials: T
authors.lastname: Noguchi
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D006348:Cardiac Surgical Procedures / Q000009:adverse effects; D004334:Drug Administration Schedule; D016903:Drug Monitoring; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D020108:Nicorandil / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood; D051436:Renal Insufficiency, Chronic / Q000097:blood / Q000628:therapy*; D017582:Renal Replacement Therapy / Q000009:adverse effects; D013997:Time Factors; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood
chemical_list: D014665:Vasodilator Agents; D020108:Nicorandil